Central nervous system tumors in donors: misdiagnosis carries a high morbidity and mortality

TitleCentral nervous system tumors in donors: misdiagnosis carries a high morbidity and mortality
Publication TypeJournal Article
Year of Publication2005
AuthorsBuell JF, Gross T, Alloway RR, Trofe J, Woodle ES
JournalTransplant Proc
Pagination583 - 4
Date PublishedMar
Accession Number15848464
Keywords*Diagnostic Errors, *Tissue Donors, Brain Death, Central Nervous System Neoplasms / *diagnosis, Humans, Kidney Transplantation / *mortality / *pathology, Liver Transplantation / mortality / pathology, Lung Transplantation / mortality / pathology, Neoplasms / mortality, Ohio, Postoperative Complications / mortality, Registries, Reoperation, Survival Analysis

INTRODUCTION: The cost of misdiagnosis of central nervous system (CNS) tumors in donors has not been previously described. The purpose of this study was to examine the Israel Penn International Transplant Tumor Registry experience with these donors. METHODS: All cases where an error in diagnosis was made due to intracranial hemorrhage from undiagnosed CNS tumors and where CNS metastases were misdiagnosed as primary brain tumor were examined. RESULTS: Forty-two organ recipients with misdiagnosed primary brain deaths from 29 donors were examined. After transplantation these donors were identified with: melanoma (23%), renal cell carcinoma (19%), choriocarcinoma (12%), sarcoma (10%), Kaposi's sarcoma (7%), and variable tumors (22%). The majority of patients were renal allograft recipients (84%) followed by liver (n = 4) and lung recipients (n = 1). The most commonly diagnostic error was with intracranial hemorrhage (ICH) (62%). A donor-related transmission rate of 74% (31/42) was identified among those patients with a misdiagnosed brain death. The majority of donor-transmitted cancers were identified in the recipient allograft (71%). Sixty-four percent of recipients suffered diffuse metastatic disease. Overall survival was poor, with a 5-year survival rate of 32% (10/31). Explantation was performed in 17 patients with confirmed donor-transmitted cancer, and in these patients a survival benefit was noted (10/17, 59%, vs 0/14, 0%; P

Notify Library Reference ID241

Related Incidents